AUG 17, 2022 5:45 PM PDT

A new software platform to help with drug discovery efficiency

WRITTEN BY: J. Bryce Ortiz

The process of drug discovery and development is expensive. A recent report from the Journal of the American Medical Association found that the median cost to bring a single new drug to market was close to a billion dollars, at $985million US dollars. Overall, in the year 2019, the pharmaceutical industry spent $83billion on research and development of potential new drugs. Clearly, developing new drugs is a pricey process and many potential drugs never make it to market. 

Drugs that never make it to market, or failed drugs, are one of the main reasons for the high cost of drug development. A recent article found that 90% of drugs fail to make it out of clinical trials, and this number is even higher for drugs that fail to move past discovery. And while there are many reasons for drug failure, the software company Dotmatics is hoping to help drug discoverers reduce human error, reduce failure rate, and reduce research and development cost. 

The company announced last month the release of its Small Molecule Drug Discovery Solution, a new software platform that helps automate workflows and improve data management. Mike McKee, president of Dotmatics said, “While small molecule science is making incredible progress, the cost of the drug discoveries is higher than ever, burdened by complex workflows and fragmented data and analysis solutions, we want to drastically improve this process by developing an integrated platform that features a great breadth of tools.”

With the software, researchers have access to tools that aid in sample logistics, quality control analysis, and a tool called structure-activity relationship which helps in the early process of drug discovery. See video above for details. 

For now, the process of drug discovery and development is still a complex and difficult process. However, Dotmatics software will help researchers streamline their processes and hopefully help to more efficiently and cost-effectively discover new drugs to treat patients and improve health. 

 

Sources: JAMACongressional Budget OfficeActa Pharmaceutic Sinica BDotmatics;

About the Author
PhD in Neuroscience
Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
JUL 14, 2022
Clinical & Molecular DX
Emerging Research Could Soon Solve the Parkinson's Disease Diagnosis Challenge
JUL 14, 2022
Emerging Research Could Soon Solve the Parkinson's Disease Diagnosis Challenge
Parkinson’s disease is a brain disorder with symptoms that begin gradually and worsen over time. Symptoms of Parki ...
JUL 16, 2022
Drug Discovery & Development
Whole Blood Exchange May Reduce Amyloid Plaques in Alzheimer's
JUL 16, 2022
Whole Blood Exchange May Reduce Amyloid Plaques in Alzheimer's
Whole blood exchange reduces the formation of amyloid beta plaques in mouse models of Alzheimer's disease. The corre ...
JUL 16, 2022
Drug Discovery & Development
Oxytocin Nasal Sprays Don't Improve Emotion Recognition in Healthy Individuals
JUL 16, 2022
Oxytocin Nasal Sprays Don't Improve Emotion Recognition in Healthy Individuals
Oxytocin nasal sprays do not improve the recognition of emotions such as anger and sadness in healthy men without autism ...
AUG 16, 2022
Drug Discovery & Development
Blood Pressure Drug Shows Promise for Treating ALS
AUG 16, 2022
Blood Pressure Drug Shows Promise for Treating ALS
Terazosin, a drug currently approved to treat high blood pressure and enlarged prostate, may also be able to treat ALS. ...
AUG 30, 2022
Clinical & Molecular DX
Caffeine Metabolite Could Slow Progression of Nearsightedness in Children
AUG 30, 2022
Caffeine Metabolite Could Slow Progression of Nearsightedness in Children
Myopia, also known as nearsightedness, is a common vision condition in which objects far away appear blurry. Myopia occu ...
SEP 17, 2022
Drug Discovery & Development
Daily Multivitamin May Slow Down Cognitive Decline in Older Adults
SEP 17, 2022
Daily Multivitamin May Slow Down Cognitive Decline in Older Adults
Daily multivitamins may slow down cognitive decline among older adults. The corresponding study was published in Alzheim ...
Loading Comments...